Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
The Revivent TC Transcatheter Ventricular Enhancement System is a micro-anchor and tether system intended for minimally invasive left ventricular (LV) restoration in patients with LV scar/aneurysm and heart failure.
The OCS Liver is a portable extracorporeal liver perfusion and monitoring system indicated for preservation and monitoring of hemodynamics and metabolic function which allows for ex-vivo assessment of liver allografts from donors after brain death (DBD) or liver allografts from donors after circulatory death (DCD) ≤ 55 years old and with ≤ 30 minutes of warm ischemic time, ma…
Aduhelm (aducanumab) is an intravenously administered amyloid beta-directed antibody for the treatment of Alzheimer disease.
Lecanemab (formerly, BAN2401) is an investigational, intravenously administered anti-amyloid beta (Aβ) protofibril antibody proposed for the treatment of early Alzheimer disease.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of RhinAer (Aerin Medical) for improvement of symptoms of chronic rhinitis.
This report evaluates the clinical utility of pharmacogenomic testing to inform the selection or dose of medications for individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD) to improve clinical outcomes.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Tenex (Tenex Health TX) to administer percutaneous ultrasonic tenotomy to reduce pain and improve quality of life and function in patients with elbow tendinopathy.
Mavacamten is an investigational oral myosin inhibitor that targets the underlying molecular mechanisms of hypertrophic cardiomyopathy (HCM). It is proposed for the treatment of patients with symptomatic obstructive HCM.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Cala Trio (Cala Health Inc.) for treatment of essential tremor.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of medial cluneal nerve (MCN) blocks for patients with lower back pain (LBP) thought to be due to MCN entrapment (MCN-E).